MISSISSAUGA, Ontario, Oct. 12, 2022 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is happy to announce that its Board of Directors has declared a quarterly dividend of $0.04 per widespread share, payable in Canadian Dollars on December 15, 2022, to shareholders of file on the shut of business on November 30, 2022. This dividend qualifies as an ‘eligible dividend’ for Canadian revenue tax functions. The declaration, timing, quantity and cost of future dividends stay on the discretion of the Board of Directors.
About BioSyent Inc.
Listed on the TSX Venture Exchange underneath the buying and selling image “RX”, BioSyent is a worthwhile growth-oriented specialty pharmaceutical firm targeted on in-licensing or buying progressive pharmaceutical and different healthcare merchandise which were efficiently developed, are protected and efficient, and have a confirmed observe file of enhancing the lives of sufferers. BioSyent helps the healthcare professionals that deal with these sufferers by advertising and marketing its merchandise via its neighborhood, specialty and worldwide business items.
As of the date of this press launch, the Company has 12,145,861 widespread shares excellent.
For a direct market quote for the TSX Venture Exchange and different Company monetary info please go to www.tmxmoney.com.
For additional info please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: [email protected]
Phone: 905-206-0013
Web: www.biosyent.com
This press launch could include info or statements which can be forward-looking. The contents herein symbolize our judgment, as on the launch date, and are topic to dangers and uncertainties which will trigger precise outcomes or outcomes to be materially completely different from the forward-looking info or statements. Potential dangers could embrace, however aren’t restricted to, these related to medical trials, product improvement, future income, operations, profitability and acquiring regulatory approvals.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that time period is outlined within the insurance policies of the TSX Venture Exchange) accepts accountability for the adequacy or accuracy of this press launch.
